| Disease | Prevalence Estimate | US people estimate | Statistic Used for Calculation |
| Sexually Transmitted Diseases (overall) |
approx 1 in 4 or 23.90% or 65 million people in USA |
64,999,999 |
65 million people living with an incurable STD (CDC)
|
| Syphilis |
N/A |
N/A |
No information
|
| HIV |
approx 1 in 302 or 0.33% or 900,000 people in USA |
899,999 |
900,000 Americans (NIAID, quarter are unaware)
|
| AIDS |
N/A |
N/A |
No information
|
| Genital herpes |
approx 1 in 4 or 24.63% or 67 million people in USA |
66,999,999 |
67 million people (NIAID)
|
| Human Papillomavirus |
approx 1 in 13 or 7.35% or 20 million people in USA |
19,999,999 |
20 million Americans currently infected (NIAID; CDC 2001)
|
| Chlamydia |
N/A |
N/A |
No information
|
| Gonorrhea |
N/A |
N/A |
No information
|
| HTLV |
N/A |
N/A |
uncommon
|
| chancroid |
N/A |
N/A |
No information
|
| cytomegalovirus |
approx 1 in 2 or 50.00% or 136 million people in USA |
136,000,000 |
50% approximately; almost half of young adults (NIAID)
|
| molluscum contagiosum |
N/A |
N/A |
Common.
|
| pubic lice |
N/A |
N/A |
No information
|
| scabies |
N/A |
N/A |
common
|
| Trichomoniasis |
N/A |
N/A |
No information
|
| bacterial vaginosis |
approx 1 in 424 or 0.24% or 640,000 people in USA |
640,000 |
16% of pregnant women (DSTD)
|
| Granuloma inguinale |
N/A |
N/A |
No information
|
| Non-Specific Urethritis |
N/A |
N/A |
No information
|
| Hepatitis B |
approx 1 in 181 or 0.55% or 1.5 million people in USA |
1,499,999 |
estimated 1.5 million HBV carriers in the U.S. (NWHIC); 417,000 people currently infected (CDC 2001)
|
| Syphilis -- Teratogenic Agent |
N/A |
N/A |
No information
|
| Human carcinogen -- Chronic Hepatitis C viral infection |
N/A |
N/A |
No information
|
| Human carcinogen -- Human Immunodeficiency Virus Type 1 infection |
N/A |
N/A |
No information
|
| Human carcinogen -- Infection with Human papillomavirus type 16 |
N/A |
N/A |
No information
|
| Human carcinogen -- Infection with Human papillomavirus type 18 |
N/A |
N/A |
No information
|
| Human carcinogen -- Infection with Human papillomavirus type 31 |
N/A |
N/A |
No information
|
| Human carcinogen -- Infection with Human papillomavirus type 35 |
N/A |
N/A |
No information
|
| Human carcinogen -- Infection with Human papillomavirus type 39 |
N/A |
N/A |
No information
|
| Human carcinogen -- Infection with Human papillomavirus type 45 |
N/A |
N/A |
No information
|
| Human carcinogen -- Infection with Human papillomavirus type 51 |
N/A |
N/A |
No information
|
| Human carcinogen -- Infection with Human papillomavirus type 52 |
N/A |
N/A |
No information
|
| Human carcinogen -- Infection with Human papillomavirus type 56 |
N/A |
N/A |
No information
|
| Human carcinogen -- Infection with Human papillomavirus type 58 |
N/A |
N/A |
No information
|
| Human carcinogen -- Infection with Human papillomavirus type 59 |
N/A |
N/A |
No information
|
| Human carcinogen -- Infection with Human papillomavirus type 66 |
N/A |
N/A |
No information
|
| Hepatitis A |
N/A |
N/A |
No information
|
| Hepatitis C |
approx 1 in 136 or 0.74% or 2 million people in USA |
1,999,999 |
estimated 2 to 5 million HCV chronic carriers
|
| Viral Hepatitis |
N/A |
N/A |
No information
|
| Chronic Hepatitis B |
approx 1 in 362 or 0.28% or 750,000 people in USA |
749,999 |
750,000 people in the United States (NIAID)
|
| Chronic Hepatitis C |
approx 1 in 68 or 1.47% or 4 million people in USA |
3,999,999 |
Almost 4 million Americans have antibodies indicating infection or prior exposure (NIDDK).
|
| Syphilitic aseptic meningitis |
N/A |
N/A |
No information
|
| Possible human carcinogenic exposure -- Human immunodeficiency virus type 2 |
N/A |
N/A |
No information
|
| Possible human carcinogenic exposure -- Human papillomavirus types 6 and 11 |
N/A |
N/A |
No information
|
| Possible human carcinogenic exposure -- Human papillomavirus genus beta |
N/A |
N/A |
No information
|
| HIV-1A |
N/A |
N/A |
HIV-1Accounts for about 26.7% of cases of HIV worldwide
|
| HIV-1B |
N/A |
N/A |
HIV-1B accounts for about 12.3% of cases of HIV worldwide
|
| HIV-2A |
N/A |
N/A |
No information
|
| HIV-1C |
N/A |
N/A |
HIV-1C accounts for about 47.2% of cases of HIV worldwide
|
| HIV-2B |
N/A |
N/A |
No information
|
| HIV-1D |
N/A |
N/A |
HIV-1D accounts for about 5.3% of cases of HIV worldwide
|
| HIV-1E |
N/A |
N/A |
No information
|
| HIV-1F |
N/A |
N/A |
No information
|
| HIV-1G |
N/A |
N/A |
No information
|
| HIV-1H |
N/A |
N/A |
No information
|
| HIV-1J |
N/A |
N/A |
No information
|
| HIV-1K |
N/A |
N/A |
No information
|
| HIV-1M |
N/A |
N/A |
HIV-1M accounts for about 90% of cases of HIV worldwide
|
| HIV-1N |
N/A |
N/A |
No information
|
| HIV-1O |
N/A |
N/A |
No information
|
| HIV-1, CRF11_cpx |
N/A |
N/A |
No information
|
| HIV-1, CRF13_cpx |
N/A |
N/A |
No information
|
| HIV-1, CRF04_ cpx |
N/A |
N/A |
No information
|
| HIV-1, CRF06_cpx |
N/A |
N/A |
No information
|
| HIV-1, CRF25_cpx |
N/A |
N/A |
No information
|
| HIV-1, CRF21_A2D |
N/A |
N/A |
No information
|
| HIV-1, CRF32_06A1 |
N/A |
N/A |
No information
|
| HIV-1, CRF16_ A2D |
N/A |
N/A |
No information
|
| HIV-1, CRF22_01A1 |
N/A |
N/A |
No information
|
| HIV-1, CRF26_AU |
N/A |
N/A |
No information
|
| HIV-2 |
N/A |
N/A |
No information
|
| HIV-1, CRF36_cpx |
N/A |
N/A |
No information
|
| HIV-1, CRF27_cpx |
N/A |
N/A |
No information
|
| HIV-1, CRF18_cpx |
N/A |
N/A |
No information
|
| HIV-1, CRF37_cpx |
N/A |
N/A |
No information
|
| HIV-1, CRF19_cpx |
N/A |
N/A |
No information
|
| Pediatric AIDS |
N/A |
N/A |
No information
|
| HIV-1A1 |
N/A |
N/A |
No information
|
| HIV-1A2 |
N/A |
N/A |
No information
|
| HIV-1A3 |
N/A |
N/A |
HIV-1Accounts for about 26.7% of cases of HIV worldwide
|
| HIV-1F1 |
N/A |
N/A |
No information
|
| HIV-1F2 |
N/A |
N/A |
No information
|
| HIV-1, CRF01_AE |
N/A |
N/A |
HIV-1, CRF01_AE accounts for about 3.2% of cases of HIV worldwide
|
| HIV-1, CRF33_01B |
N/A |
N/A |
No information
|
| HIV-1, CRF31_BC |
N/A |
N/A |
No information
|
| HIV-1, CRF15_01B |
N/A |
N/A |
No information
|
| HIV-1, CRF34_01B |
N/A |
N/A |
No information
|
| HIV-1, CRF02_AG |
N/A |
N/A |
No information
|
| HIV-1, CRF30_0206 |
N/A |
N/A |
No information
|
| HIV-1, CRF20_BG |
N/A |
N/A |
No information
|
| HIV-1, CRF12_BF |
N/A |
N/A |
No information
|
| HIV-1, CRF41_CD |
N/A |
N/A |
No information
|
| HIV-1, CRF40_BF |
N/A |
N/A |
No information
|
| HIV-1, CRF07_BC |
N/A |
N/A |
No information
|
| HIV-1, CRF35_AD |
N/A |
N/A |
No information
|
| HIV-1, CRF08_BC |
N/A |
N/A |
No information
|
| HIV-1, CRF42_BF |
N/A |
N/A |
No information
|
| HIV-1, CRF23_BG |
N/A |
N/A |
No information
|
| HIV-1, CRF14_BG |
N/A |
N/A |
No information
|
| HIV-1, CRF24_BG |
N/A |
N/A |
No information
|
| HIV-1, CRF05_ D/F |
N/A |
N/A |
No information
|
| HIV-1, CRF43_02G |
N/A |
N/A |
No information
|
| HIV-1, CRF17_BF |
N/A |
N/A |
No information
|
| HIV-1, CRF28_BF |
N/A |
N/A |
No information
|
| HIV-1, CRF38_BF |
N/A |
N/A |
No information
|
| HIV-1, CRF29_BF |
N/A |
N/A |
No information
|
| HIV-1, CRF39_BF |
N/A |
N/A |
No information
|
| Chlamydial Infection |
N/A |
N/A |
No information
|
| Tumours related to AIDS |
N/A |
N/A |
No information
|
| Pulmonary infections related to AIDS |
N/A |
N/A |
No information
|
| Opportunistic infections related to HIV infection |
N/A |
N/A |
No information
|
| Gastrointestinal infections related to AIDS |
N/A |
N/A |
No information
|
| HIV related skin conditions |
N/A |
N/A |
No information
|
| Neurological disorders related to AIDS |
N/A |
N/A |
No information
|
| HIV like Severe sore throat |
N/A |
N/A |
No information
|
| AIDS-Associated Nephropathy |
N/A |
N/A |
No information
|
| AIDS-Related Complex |
N/A |
N/A |
No information
|
| AIDS-Related Opportunistic Infections |
N/A |
N/A |
No information
|
| AIDS wasting syndrome |
N/A |
N/A |
No information
|
| AIDS Dementia Complex |
N/A |
N/A |
No information
|
| Vaginosis (bacterial vaginosis) |
N/A |
N/A |
No information
|
| Neurosyphilis -- general paresis |
N/A |
N/A |
No information
|
| Genital warts |
N/A |
N/A |
No information
|
| HIV/AIDS |
approx 1 in 302 or 0.33% or 900,000 people in USA |
899,999 |
900,000 Americans (NIAID, quarter are unaware)
|
| Lymphoma, AIDS-related |
N/A |
N/A |
No information
|
| Lipodystrophy-HIV related |
N/A |
N/A |
No information
|
| Tinea cruris |
N/A |
N/A |
No information
|
| Ureaplasma urealyticum |
N/A |
N/A |
No information
|
| Lymphogranuloma venereum |
N/A |
N/A |
No information
|
| Primary syphilis |
N/A |
N/A |
No information
|
| Secondary syphilis |
N/A |
N/A |
No information
|
| Tertiary syphilis |
N/A |
N/A |
No information
|
| Congenital syphilis |
N/A |
N/A |
No information
|
| HIV-associated eosinophilic folliculitis |
N/A |
N/A |
No information
|
| Treponema infection |
N/A |
N/A |
No information
|
| The clap |
N/A |
N/A |
No information
|
| Syphilis, latent |
N/A |
N/A |
No information
|
| Neurosyphilis |
N/A |
N/A |
No information
|
| Neurosyphilis -- asymptomatic |
N/A |
N/A |
No information
|
| Neurosyphilis -- tabes dorsalis |
N/A |
N/A |
No information
|
| Neurosyphilis -- meningovascular |
N/A |
N/A |
No information
|
| AIDS dysmorphic syndrome |
N/A |
N/A |
No information
|
| Condyloma |
N/A |
N/A |
No information
|
| Durand-Nicolas-Favre syndrome |
N/A |
N/A |
No information
|
Worldwide, an estimated 333 million new cases of four curable
STDs (gonorrhea, chlamydial infection, syphilis and
trichomoniasis) occurred in 1997. (Source: excerpt from
The following statistics relate to the prevalence of Sexually Transmitted Diseases:
The medical term 'prevalence' of Sexually Transmitted Diseases usually refers to the estimated population
of people who are managing Sexually Transmitted Diseases at any given time,
whereas the annual diagnosis rate of new cases of Sexually Transmitted Diseases is called the 'incidence'.
For more information on prevalence and incidence statistics, see about prevalence and incidence statistics.
